Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
BCAB
BCAB
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BCAB News
Smith & Wesson Exceeds Q3 Earnings Expectations
4d ago
Benzinga
BioAtla Initiates Strategic Review to Maximize Shareholder Value
Mar 02 2026
Newsfilter
STMicroelectronics Shares Rise 4.3% in Pre-Market Trading
Feb 09 2026
Benzinga
Healthcare Stocks with Strong Earnings Momentum Earn A+ EPS Revision Grades
Jan 16 2026
seekingalpha
Alumis Inc. (ALMS) Shares Surge 17.33% on Phase 3 Clinical Trial Data Announcement
Jan 06 2026
NASDAQ.COM
GH Research PLC Shares Surge 18.1% on FDA IND Status Update Announcement
Jan 05 2026
Benzinga
BioAtla Secures $5 Million for Oz-V Phase 3 Clinical Trial Expenses
Dec 31 2025
Globenewswire
BioAtla Secures $5 Million for Oz-V Phase 3 Clinical Trial Expenses
Dec 31 2025
Newsfilter
After-Hours Stock Surge: Exicure Leads with 72% Increase, Followed by Wave Life and Assembly Biosciences
Dec 09 2025
NASDAQ.COM
Biotech Stocks Surge in After-Hours Trading with Gains from BioAtla, Entero, and Sonnet
Dec 01 2025
NASDAQ.COM
BioAtla Secures Flexible Financing Agreements Worth Up to $22.5 Million
Nov 21 2025
Newsfilter
VTI ETF Daily Update - November 14, 2025
Nov 14 2025
TipRanks
Applied Therapeutics, Omeros, and Others Experience Significant Price Changes After Market Close
Nov 14 2025
NASDAQ.COM
BioAtla sets $800M peak sales goal for Oz-V following FDA alignment for phase III launch
Nov 13 2025
SeekingAlpha
Daily Update on Vanguard Total Stock Market ETF (VTI) — November 13, 2025
Nov 13 2025
TipRanks
VTI ETF Daily Update: Key Insights for Investors—November 12, 2025
Nov 12 2025
TipRanks
Show More News
